These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [The effect of ethyl-chlorophenoxyisobutyrate on the serum lipids in coronary sclerosis]. Keller L, Rétsági G, Sebestyén M, Diczendy S, Erdélyi G. Z Gesamte Inn Med; 1966 Mar 15; 21(6):169-72. PubMed ID: 5988081 [No Abstract] [Full Text] [Related]
9. [Action mechanism and clinical success of Regelan (Clofibrate)]. Fitzgerald JD. Wien Klin Wochenschr; 1967 Sep 29; 79(39):716-20. PubMed ID: 5595437 [No Abstract] [Full Text] [Related]
10. [Prolonged use of atromid in patients with coronary arteriosclerosis]. Zadionchenko VS. Kardiologiia; 1967 Oct 29; 7(10):32-5. PubMed ID: 5607197 [No Abstract] [Full Text] [Related]
13. Observations on the effect of ethyl a-p chlorophenoxyisobutyrate (CPIB) therapy on serum lipid levels and on diabetic and some other retinopathies. Vannas S, Esilä R, Tuovinen E. Acta Ophthalmol (Copenh); 1968 Dec 20; 46(2):162-70. PubMed ID: 5755673 [No Abstract] [Full Text] [Related]
14. [Effect of Atromid on blood lipids in patients with hyperlipemia]. Baranova LV. Ter Arkh; 1968 Mar 20; 40(3):15-20. PubMed ID: 4875984 [No Abstract] [Full Text] [Related]
17. [Long-term treatment of previously therapy-resistant cases of primary hypertriglyceridemia of the adult with ethyl-p-chlorophenoxyisobutyrate]. Braunsteiner H, Herbst M, Sandhofer F, Sailer S. Dtsch Med Wochenschr; 1967 Dec 15; 92(50):2302-8. PubMed ID: 6075896 [No Abstract] [Full Text] [Related]